Hikma Pharmaceuticals PLC (HIKl)

Currency in GBP
1,985.00
-13.00(-0.65%)
Closed·
HIKl Scorecard
Full Analysis
Has raised its dividend for 8 consecutive years
HIKl is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1,984.002,001.00
52 wk Range
1,751.002,356.00
Key Statistics
Bid/Ask
1,985.00 / 1,987.00
Prev. Close
1,998
Open
1,986
Day's Range
1,984-2,001
52 wk Range
1,751-2,356
Volume
59.01K
Average Volume (3m)
89.47K
1-Year Change
5.83%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HIKl Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Hikma Pharmaceuticals PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Hikma Pharmaceuticals PLC Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Generics segment offers oral, respiratory, and other generic and specialty products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.

Employees
9500

Compare HIKl to Peers and Sector

Metrics to compare
HIKl
Peers
Sector
Relationship
P/E Ratio
16.2x13.3x−0.5x
PEG Ratio
0.180.250.00
Price/Book
2.5x1.9x2.6x
Price / LTM Sales
1.9x2.2x3.2x
Upside (Analyst Target)
-−3.9%41.2%
Fair Value Upside
Unlock25.0%6.2%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.62%
Dividend Yield
3.12%
Industry Median 2.51%
Annualised payout
61.91
Paid unevenly
5-Years Growth
+12.70%
Growth Streak

Earnings

Latest Release
Mar 19, 2025
EPS / Forecast
0.60 / --
Revenue / Forecast
1.56B / --
EPS Revisions
Last 90 days

HIKl Income Statement

People Also Watch

255.30
LGEN
-0.04%
415.00
WPP
-2.12%
11,158.0
AZN
+3.41%
525.00
NWG
+2.02%
2,598.0
CRDA
-10.38%

FAQ

What Stock Exchange Does Hikma Pharmaceuticals PLC Trade On?

Hikma Pharmaceuticals PLC is listed and trades on the BATS Europe stock exchange.

What Is the Stock Symbol for Hikma Pharmaceuticals PLC?

The stock symbol for Hikma Pharmaceuticals PLC is "HIKl."

What Is the Hikma Pharmaceuticals PLC Market Cap?

As of today, Hikma Pharmaceuticals PLC market cap is 4.38B.

What Is Hikma Pharmaceuticals PLC's Earnings Per Share (TTM)?

The Hikma Pharmaceuticals PLC EPS (TTM) is 1.62.

From a Technical Analysis Perspective, Is HIKl a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Hikma Pharmaceuticals PLC Stock Split?

Hikma Pharmaceuticals PLC has split 0 times.

How Many Employees Does Hikma Pharmaceuticals PLC Have?

Hikma Pharmaceuticals PLC has 9500 employees.

What is the current trading status of Hikma Pharmaceuticals PLC (HIKl)?

As of 29 Jul 2025, Hikma Pharmaceuticals PLC (HIKl) is trading at a price of 1,985.00, with a previous close of 1,998.00. The stock has fluctuated within a day range of 1,984.00 to 2,001.00, while its 52-week range spans from 1,751.00 to 2,356.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.